CME INDIA Presentation by Dr. N. K. Singh, Diabetes Care Physician, Dhanbad, Editor-in Chief, CME INDIA.

Based on a presentation at Diacarecon, Ahmedabad, 2025.

What is Steatosis (Fatty Liver)

Definition: Accumulation of fat (triglycerides) inside liver cells (hepatocytes).

Cause: Commonly due to obesity, diabetes, alcohol, high cholesterol, certain drugs, or metabolic dysfunction–associated steatotic liver disease (MASLD, previously NAFLD).

Reversibility: Yes – if lifestyle changes are made (weight loss, exercise, diet, stopping alcohol).

Measured by FibroScan CAP (Controlled Attenuation Parameter):

S0: <238 dB/m → no steatosis

S1: 238–260 → mild

S2: 260–290 → moderate

S3: >290 → severe

Think of steatosis as “fat in the liver” – the earliest change.

Fibrosis (Scarring of Liver)

Definition: Formation of scar tissue in the liver due to chronic injury (alcohol, hepatitis, MASLD, toxins).

Mechanism: The liver tries to repair damage, but repeated injury leads to collagen deposition and scarring.

Reversibility: Early fibrosis (F1–F2) may be partly reversible; advanced fibrosis and cirrhosis (F3–F4) are harder to reverse.

Measured by FibroScan stiffness (kPa):

F0: <6 kPa → no fibrosis

F1: 6–7 kPa → mild fibrosis

F2: 7–9 kPa → significant fibrosis

F3: 9–12 kPa → advanced fibrosis

F4: >12–14 kPa → cirrhosis

Think of fibrosis as “scar tissue in the liver” – more serious than steatosis

Knowing this is Important

What is Transient Elastography (TE)

A technique that uses a vibration pulse and ultrasound waves to measure liver stiffness.

Principle: A mechanical vibration generates a shear wave through the liver, and ultrasound measures how fast the wave travels. Faster wave = stiffer liver (fibrosis).

Output: Stiffness in kilopascals (kPa) and often CAP score (dB/m) for fat. Use: Detects fibrosis and steatosis in a non-invasive, painless way. It’s a method, not a machine.

What is FibroScan?

A specific device/brand (by Echosens, France) that performs transient elastography.

It is the most widely used machine for TE in liver disease.

Provides: LSM (liver stiffness measurement, kPa) → fibrosis

CAP (controlled attenuation parameter, dB/m) → steatosis

Other companies also make TE machines, but FibroScan is the original and most validated

History of FibroScan (TE)

• Early Concept (1990s)
  • Traditional liver biopsy was the gold standard for fibrosis, but it was invasive, painful, and had sampling errors.
  • Researchers in France began exploring non-invasive methods based on ultrasound elastography to measure liver stiffness.
• Development Phase (Late 1990s – Early 2000s)
  • The principle of transient elastography was developed: low-frequency vibrations generate shear waves, and ultrasound tracks their velocity to calculate tissue stiffness.
  • Early prototypes were tested at Pitié-Salpêtrière Hospital, Paris.
• First Commercial Launch (2003)
  • FibroScan (by Echosens, France) became the first commercial transient elastography device.
  • Initially validated in chronic hepatitis C, showing high accuracy in detecting advanced fibrosis and cirrhosis.
• Global Expansion (2005–2015)
  • Rapid adoption in Europe and Asia, later in the US (FDA approval in 2013).
  • Applications expanded from viral hepatitis to MASLD (NAFLD/NASH), alcoholic liver disease, autoimmune hepatitis, and cholestatic disorders.
  • Addition of Controlled Attenuation Parameter (CAP) in 2010 allowed simultaneous assessment of steatosis.
• Recent Advances (2016–Present)
  • Broader use in primary care, endocrinology, and diabetes clinics for MASLD screening.
  • Development of XL probe for obese patients and M+ probe for pediatrics.
  • Incorporated into guidelines (AASLD, EASL, APASL) as a first-line tool for fibrosis risk stratification.
  • Current research explores combination with biomarkers (Fib-4, ELF, FAST score) for precision diagnosis and monitoring

Key Differences at a Glance

• TE (FibroScan): Portable, fast, screening tool, validated cut-offs, but blind and limited in ascites/obesity.
• SWE: US-guided, detailed elastogram, works in ascites/obesity, more versatile, but less standardized and needs US expertise.
• Use *FibroScan (TE) when you want quick, standardized fibrosis/steatosis staging in large populations.
• Use SWE when you need precise, US-guided, focal liver assessment or in difficult patients (ascites, obesity, lesions).

Fib-4 is the New Mantra in Diabetes Care

When you get a report of Fibro scan, what to see?

This report shows:

• Median Liver Stiffness (E): 6.1 kPaI
• QR: 0.3 kPa →
• IQR/Median ratio: 5% (very reliable, <30% acceptable)Valid 
• Measurements: 11 (meets quality criteria, ≥10 required)
• Shear Wave Speed (Vs): 1.42 m/sCAP 
• (Controlled Attenuation Parameter): 232 dB/m (measures liver fat)

Interpretation

Fibrosis (Stiffness)

Normal liver: ~2.5–5.5 kPa

Borderline zone: 5.5–7 kPa → may indicate early fibrosis (F1–F2), depending on context

Significant fibrosis (≥F2): >7–8 kPa

Cirrhosis (F4): >12–14 kPa➡ Your result: 6.1 kPa

This report:

6.1 kPa

Slightly above normal but below the threshold for significant fibrosis.

Consistent with F0–F1 (no to mild fibrosis).

Next to See:

Steatosis (Fat in Liver, CAP Score)

Final Impression:

Another Case

Reliability of Scan

• At least 10 valid readings required → You have 11.
• IQR/Median <30% → 
• Your ratio is 13%, so results are highly reliable.
• Clinical Implications
• Liver stiffness is normal.
• Suggests absence of advanced liver disease (fibrosis/cirrhosis).
• If liver enzymes (ALT, AST) are normal and there are no risk factors (alcohol, viral hepatitis, metabolic syndrome, MASLD/NAFLD), this scan is reassuring.
• Recommendations:
  • Maintain healthy lifestyle: balanced diet, avoid excess alcohol, maintain healthy weight.
  • If you have risk factors (diabetes, obesity, viral hepatitis, fatty liver), continue routine follow-up with liver function tests and periodic scans. Otherwise, no evidence of chronic liver damage at present.
• Final Impression: FibroScan is normal (3.2 kPa), no evidence of significant fibrosis or cirrhosis.

What the Clinician needs to know?

CME INDIA Take Away Points

1. Understand the Two Key Outputs: LSM & CAP

FibroScan provides:

• Liver Stiffness Measurement (LSM, kPa) → estimates fibrosis
• Controlled Attenuation Parameter (CAP, dB/m) → estimates steatosis

Both must be interpreted together, not in isolation.

2. LSM Values Reflect Fibrosis Stage (Approximate Cut-offs)

Typical thresholds (MASLD context):

• <7 kPa → F0–F1 (Low risk)
• 7–9 kPa → F2 (Intermediate risk)
• ≥10 kPa → F3–F4 (High risk / advanced fibrosis)
• ≥12–14 kPa → suggestive of cirrhosis

These are not absolute; integrate with clinical context.

3. CAP Score Reflects Fat Content (Steatosis Grading)

Typical CAP cut-offs:

• S1 (mild): 248–267 dB/m
• S2 (moderate): 268–279 dB/m
• S3 (severe): ≥280 dB/m

Useful for diagnosis of MASLD in diabetes.

4. FIB-4 Should Always Be Checked Before FibroScan

If FIB-4 >1.3 (age <65) or >2.0 (age >65) → proceed to FibroScan.

Combining FIB-4 + FibroScan improves accuracy and reduces unnecessary referrals.

5. Interpreting Results in Obesity Requires Caution

Obesity (BMI ≥30 kg/m²) can:

• Artificially increase LSM
• Reduce CAP accuracy
• Require XL probe instead of M-probe

If incorrect probe used → unreliable values.

6. Inflammation, Cholestasis, or Congestive Heart Failure Can Falsely Elevate LSM

LSM increases with:

• Acute hepatitis (ALT >100–200 IU/L)
• Cholestasis / biliary obstruction
• Severe hepatic congestion (heart failure)

In these cases, repeat FibroScan after resolution.

7. Adequate Fasting Is Essential

Patients should be:

• Fast ≥3-4 hours
  Food intake increases liver blood flow → false high LSM.

8. Reliability Criteria Must Be Met

A FibroScan is reliable when:

• ≥10 valid measurements
• IQR/median ≤30% for LSM
• Success rate >60%

If criteria not met → repeat test or use alternative modality.

9. Follow-up Intervals Based on LSM (as in your table)

• Low risk (<7 kPa): repeat every 2 years
• Intermediate risk (7–9 kPa): every 12–18 months
• High risk (≥10 kPa): every 6–12 months

Patients with cirrhosis require:

• 6-monthly US for HCC
• Variceal screening

10. Interpretation Must Be Integrated Clinically, Not Used Alone

FibroScan does not replace:

• Liver biopsy in complex cases
• Assessment of comorbidities (diabetes, obesity, dyslipidemia)
• Evaluation of alcohol intake, medications, viral hepatitis

Always interpret with:

• ALT, AST
• Platelet count
• Metabolic profile
• Imaging
• Fibrosis scores (fib-4, nfs)

Bonus (Important for Diabetes Clinics):

• Diabetic patients have a 2–3× higher prevalence of advanced fibrosis even with normal ALT.
• FibroScan should be routinely considered in T2DM + obesity + elevated FIB-4.

CME INDIA Tail-Piece

Suggested Readings:

1. American Diabetes Association. (2025). Metabolic dysfunction-associated steatotic liver disease: Consensus report and clinical recommendations. Diabetes Care, 48(7), 1057–1076. https://doi.org/10.2337/dc25-xxxx
2. Zhang, Y., Liu, H., Chen, Q., & Wang, L. (2025). Liver elastography for liver fibrosis stratification: Updated evidence and clinical utility. Biomedicines, 13(1), 138. https://doi.org/10.3390/biomedicines13010138
3. Patel, R., Wong, V. W., Rinella, M., & Yilmaz, Y. (2025). Staging liver fibrosis and cirrhosis using non-invasive tests: Updated systematic review and meta-analysis. Liver Research, 12(2), 134–149. https://doi.org/10.1016/j.livres.2024.11.004
4. Li, X., Zhou, S., Chen, Y., & Huang, J. (2025). The accuracy of FibroScan, FIB-4, and NAFLD fibrosis score in patients with type 2 diabetes mellitus. Medicine, 104(25), e35123. https://doi.org/10.1097/MD.0000000000035123

---

---

Discover CME INDIA

• Explore CME INDIA Repository
• Examine CME INDIA Case Study
• Read History Today in Medicine
• Register for Future CMEs

---